Full text is available at the source.
Abstract
Semaglutide and tirzepatide are primary treatments for cardiometabolic disease.
- The comparative cardiovascular safety of semaglutide and tirzepatide is not fully characterized.
- Further investigation may be necessary to understand their real-world effects.
- Insights into their safety profiles could inform treatment decisions for patients with cardiometabolic conditions.
Simplified